Zealand Pharma A/S and its partner, Sanofi SA, have presented further data supporting their candidate treatment for Type 2 diabetes, lixisenatide (Lyxumia). Lixisenatide is a glucagon-like peptide-1 agonist. ---Subscribe to MedNous to access this article--- Company News Clinical Research
